Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News C4 Therapeutics Inc CCCC

Healthcare Biotechnology
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against... see more

Recent & Breaking News (NDAQ:CCCC)

C4 Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire February 24, 2021

C4 Therapeutics to Participate in BMO BioPharma Spotlight Series

GlobeNewswire February 11, 2021

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies

GlobeNewswire January 19, 2021

C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2021

C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022

GlobeNewswire January 6, 2021

C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

GlobeNewswire December 17, 2020

C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx

GlobeNewswire November 25, 2020

C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

GlobeNewswire November 13, 2020

C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

GlobeNewswire November 12, 2020

C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit

GlobeNewswire October 14, 2020

C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire October 6, 2020

C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering

GlobeNewswire October 1, 2020